TheraVectys是主要在法国和美国开展业务的免疫治疗公司，由巴斯德研究所(Pasteur Institute)分拆，致 力开发用于预防和治疗癌症及其他疾病的慢病毒载体(lentiviral vectors)，其支持者包括Tethys Invest SAS。 外国生物科技公司通常会选择欧洲或美国市场上市，对于非中资生物科技公司来说，赴港上市仍属少见 之举。不过，中国正挑战西方在医疗创新领域的主导地位，并重塑生物科技产业格局。数据显示，医疗 健保公司去年在香港股市共融资约130亿美元。 据媒体报道，法国生物科技公司TheraVectys SA正考虑来香港IPO。知情人士称，TheraVectys正与顾问 评估或集资数亿美元的IPO方案，最快今年进行。TheraVectys代表暂未回应。 ...

Bagsværd, Denmark, 31 December 2025 – Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent. Novo Nordisk is pleased that the Court has upheld the Beijing IP Court ruling recognising the validity of the semaglutide compound patent. “This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,” said Mike Doustdar, president and CEO of Novo Nordisk. ...

这一过程导致了极高的生产成本与终端价格。施凯凯表示，目前传统CAR-T在国内的定价普遍在100万 至120万元人民币，即便有商业保险覆盖，对于绝大多数家庭而言依然难以承受。此外，复杂的制备周 期让病情进展迅速的患者面临一定风险。 旨在解决上述痛点的"体内CAR-T"技术，因其无需体外细胞制备、可直接在患者体内完成改造的"现货 化"潜力，成为了全球制药巨头争夺的战略高地。据行业数据统计，仅在2025年内，就发生了多起并购 交易。 新华财经上海12月31日电 随着首版《商业健康保险创新药品目录》落地，嵌合抗原受体T细胞（CAR- T）疗法再次成为关注焦点。虽然数款产品被纳入目录，但"百万一针"的天价标签与复杂的定制化制备 流程，依然是横亘在患者与治愈希望之间的巨大鸿沟。 在传统CAR-T疗法仍陷于价格与工艺困局之时，行业将目光聚焦在体内CAR-T（In Vivo CAR-T）这一 新技术路线。2025年，跨国药企（MNC）在这一领域加速布局，多起十亿美元级的收购案显示出行业 对这一新技术的高预期。 虽然技术共识尚未达成，但国内入局企业已过百家。锋寻生物创始人兼CEO施凯凯在接受记者采访时表 示，未来1至2年将是技 ...

年终分享。 作者/周佳丽 2 0 2 5年已近尾声，若要回顾今年创投圈的关键时刻，创新药高涨一幕无法略过。 回想前两年，医疗行业经历估值回调，医疗投资一度趋于沉寂。市场情绪悲观之际，启明创投主管合伙人胡旭波却和团队做出重要决 策——继续重点投资创新药和器械领域，尤其是有重大临床突破潜力的领域。 今年11月，康诺思腾完成约2亿美元的超募融资，吸引了包括港投公司、全球战略投资者及主权基金在内的多方参与，老股东启明创 投等继续加持。这已经是启明创投连续五轮投资康诺思腾。 几天后，启明创投还将迎来一个重要I PO——英矽智能，一家总部在香港、研发中心在上海的AI新药研发企业。启明创投是英矽智能 的早期投资人之一，并在后续多轮融资中持续加注。英矽智能发展早期，启明投资团队就开始协助支持公司建立起新药研发领导团 报道/投资界PEdaily 现在回头看，当初的决定看起来是个正确的选择：今年，创新药板块成为明星，港股盛况更是历历在目——I PO钟声不断，十倍股频 现，指数一度飙升逾1 0 0 %。甚至有投资人将2 0 2 5年称为"医药翻身之年"。 "这只是开始。"行至年终，胡旭波与投资界聊起中国医疗创新的起起伏伏。他相信， ...

MACD金叉信号形成，这些股涨势不错！ 责任编辑：杨赐 (同)华宝基金 te not teams T+0交易 港股通国家ETFLE s so ge MACD金叉信号形成，这些股涨势不错！ 责任编辑：杨赐 ...

复旦管院 公共卫生是离"不确定性"最近的学科之一，与千万人的健康安全息息相关。怎样构建传染病的大众防治 生态，怎样让创新医疗技术平等惠及更多人群？作为复旦管院科创赋能实践五周年"特别呈现"，12月16 日，"复旦管院恢复建院40周年·领变者论坛"在政立院区举行。国家传染病医学中心主任、复旦大学感 染与健康研究院院长、复旦大学附属华山医院感染科主任张文宏教授发表"创新与医疗不平等——如何 弥合鸿沟"主题演讲，分享了对医疗技术创新、优化资源配置、医疗模式变革等方面的探索与思考。 创新要可持续，公平不能忘 创新能为医疗带来巨大改变，但也可能带来新问题，甚至加剧社会不平等。如果这种不平等持续扩大， 就会形成难以跨越的社会鸿沟。创新不是个人选择，而是时代发展的必然趋势。 真正的创新动力来自社会，只有为人类幸福创造价值的创新才是可持续的。每一次创新都会带来改变， 但在推动进步的同时，我们必须关注平等与公正。 过去，我国医疗资源城乡差距明显，农村卫生院水平有限。因此，国家推动了一系列改革，努力缩小这 一差距。 传统医疗鸿沟主要来自经济壁垒，体现在三方面： 一是尖端疗法价格太高。像基因治疗、个性化抗癌药、脑机接口等技术，因研 ...

近日，齐济投资宣布旗下人民币二期基金完成首关募集，募集规模达9亿元人民币。此次首关完成，为齐济后续在医疗健康领域的投资布局打下根 基，也为推动医疗领域创新与突破贡献力量。 在齐济一期基金的投资实践中，团队已成功领导投资了一系列著名企业家、科学家在关键领域和重要市场的创业项目。 持续打造"神枪手"级投资团 队，构建精准投资体系一直是齐济投资的战略重点。 每日｜荐读 论坛： 新一批敲钟人，已在路上 荐读： 重新发现香港：科创时代的新蓝图 榜单： 全国首只AIC产业母基金来了 热文： 投资人"忙疯了" 据悉，齐济二期将继续深度聚焦于全球前沿技术驱动的医疗健康与生命科学领域，锚定具备全球竞争力的源头创新成果进行投资，以差异化策略引领 产业价值创造，推动医疗健康事业的持续进步。 齐济投资主要关注前沿技术驱动的生物制药、医疗器械和体外诊断等领域的优质投资机会，聚焦具备显著优势的细分赛道，重点关注全球医疗市场以 及病患"未满足的需求"，坚持为被投企业赋能和创造协同价值，共同推进医疗创新，为社会创造价值。 来源：齐济投资 ...

Core Insights - Liu Rong, a prominent figure in the field of hepatobiliary surgery, has pioneered numerous surgical techniques and innovations, including the world's first low-orbit satellite remote surgery and various robotic surgeries [5][8][9] - The focus of Liu Rong's work is on improving patient outcomes through advanced surgical methods, emphasizing the importance of innovation in addressing previously untreatable conditions [8][10] Group 1: Achievements and Innovations - Liu Rong has led his team to complete over 30,000 complex hepatobiliary surgeries and more than 12,000 robotic surgeries, establishing a comprehensive minimally invasive surgical theory and technique system [4][5] - He has successfully performed the world's first single-port robotic surgery for pancreatic islet cell tumors and the first 5G remote surgical animal experiment [8][9] - The introduction of robotic surgery has significantly reduced surgery time from 6-7 hours to 2-3 hours, with many patients discharged within 2-3 days post-operation [9] Group 2: Educational Contributions and Team Development - Liu Rong actively promotes new technologies and trains grassroots medical personnel, believing that a strong team is essential for advancing surgical capabilities [12] - He has authored several key publications and guidelines in the field, contributing to the education and training of surgeons in hepatobiliary surgery [12] - Liu Rong has been involved in organizing international forums and training sessions to share the latest research and surgical techniques with peers [12]

Core Insights - The first Global Innovation Medical Devices and Pharmaceuticals Expo in Boao, Hainan, aims to create a platform for global medical technology exchange and cooperation, gathering around 700 representatives from governments, medical institutions, research institutes, universities, and enterprises [1][2] Group 1: Event Overview - The expo is themed "Intelligent Gathering of Global Innovative Technologies, Building a Healthy Future for Humanity" and focuses on the trends in global innovative pharmaceuticals and medical technology research and clinical applications [1] - Over 100 international innovative medical devices, special medical foods, and new biomedical technologies were launched during the event [1] Group 2: Key Initiatives - The expo initiated the establishment of an Expert Committee for the Introduction of Innovative Medical Devices, aimed at enhancing the scientific decision-making process for the introduction of innovative medical devices and aligning clinical needs [2] - An award ceremony named "Light of Innovation" recognized representative innovative products and collaborative institutions, with multiple awards established to encourage further cooperation among stakeholders in the medical innovation field [2]

Core Insights - The first Global Innovation Drug and Medical Device Expo was held in Boao, Hainan, showcasing the significance of the event in the medical tourism sector [1] - The authoritative "White Paper on the Introduction and Use of International Innovative Drugs and Medical Devices in the Boao Lecheng International Medical Tourism Pilot Zone" was released, highlighting the region's role in medical innovation [1] Summary by Sections - **Innovative Products**: The white paper includes over 100 innovative drug and medical device products, special medical foods, health foods, and biomedical technology projects introduced in the Lecheng Pilot Zone [1] - **Patient Cases**: Real patient cases were documented, demonstrating the effectiveness and quality of life improvements from treatments received in the Lecheng area [1] - **Framework of the White Paper**: The white paper is structured around six core sections, covering international drug and device approvals, licensed imports, treatment effect case studies, real-world data applications, local production, and future introduction plans [1] - **Unique Value Proposition**: The document outlines Lecheng's unique value as a testing ground and window for medical innovation in China [1]